NCT00785460

Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Ruhr University of Bochum · Academic / Other
• Sex: All
• Age: 20 Years – 60 Years
• Healthy volunteers: Accepted

Summary

Benfotiamine pretreatment (3 days)at high dosage (1050 mg/day) prevents in healthy subjects smoking-induced vascular dysfunction assessed by ultrasound flow mediated dilatation of the brachial artery.

Detailed description

Benfotiamine pretreatment (3 days)at high dosage (1050 mg/day) prevents in healthy subjects smoking-induced vascular dysfunction assessed by ultrasound flow mediated dilatation (FMD) of the brachial arteryand laboratory parameters (adhesion molecules).

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	Benfotiamine

Timeline

• Start date: 2008-01-01
• Primary completion: 2008-05-01
• First posted: 2008-11-05
• Last updated: 2008-11-05

Locations

1 site across 1 country: Germany